Photocure ASA
OSE:PHO
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
52 Week Range |
48.05
70.9
|
Price Target |
|
We'll email you a reminder when the closing price reaches NOK.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Intrinsic Value
The intrinsic value of one PHO stock under the Base Case scenario is 69.23 NOK. Compared to the current market price of 48.7 NOK, Photocure ASA is Undervalued by 30%.
The Intrinsic Value is calculated as the average of DCF and Relative values:
Valuation Backtest
Photocure ASA
Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.
Start backtest now and learn if your stock is truly undervalued or overvalued!
Stock is trading at its lowest valuation over the past 5 years.
To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.
The backtest for PHO cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.
Fundamental Analysis
Economic Moat
Photocure ASA
Select up to 3 indicators:
Select up to 3 indicators:
Months
Months
Months
Months
Select up to 2 periods:
Revenue & Expenses Breakdown
Photocure ASA
Balance Sheet Decomposition
Photocure ASA
Current Assets | 387.6m |
Cash & Short-Term Investments | 267m |
Receivables | 85.9m |
Other Current Assets | 34.7m |
Non-Current Assets | 325.9m |
PP&E | 35.9m |
Intangibles | 248.2m |
Other Non-Current Assets | 41.8m |
Current Liabilities | 66.7m |
Accounts Payable | 16.2m |
Other Current Liabilities | 50.4m |
Non-Current Liabilities | 147.3m |
Other Non-Current Liabilities | 147.3m |
Earnings Waterfall
Photocure ASA
Revenue
|
513.6m
NOK
|
Cost of Revenue
|
-28.1m
NOK
|
Gross Profit
|
485.4m
NOK
|
Operating Expenses
|
-445.4m
NOK
|
Operating Income
|
40m
NOK
|
Other Expenses
|
-27.2m
NOK
|
Net Income
|
12.8m
NOK
|
Free Cash Flow Analysis
Photocure ASA
NOK | |
Free Cash Flow | NOK |
PHO Profitability Score
Profitability Due Diligence
Photocure ASA's profitability score is 40/100. The higher the profitability score, the more profitable the company is.
Score
Photocure ASA's profitability score is 40/100. The higher the profitability score, the more profitable the company is.
PHO Solvency Score
Solvency Due Diligence
Photocure ASA's solvency score is 79/100. The higher the solvency score, the more solvent the company is.
Score
Photocure ASA's solvency score is 79/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
PHO Price Targets Summary
Photocure ASA
According to Wall Street analysts, the average 1-year price target for PHO is 101.75 NOK with a low forecast of 84.84 NOK and a high forecast of 126 NOK.
Dividends
Current shareholder yield for PHO is .
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
Profile
Country
Industry
Market Cap
Dividend Yield
Description
Photocure ASA delivers transformative solutions to improve the lives of bladder cancer patients. The company is headquartered in Oslo, Oslo. The company went IPO on 2000-05-29. The company operates in the field of photodynamic diagnosis, cosmetics and treatment of acne, bladder cancer, colon cancer, as well as human papilloma virus (HPV) and precancerous lesions of the cervix. The Company’s activities comprise research, development and commercialization of pipeline projects within two segments: Cancer and Dermatology. Its brand portfolio includes: Hexvix and Cysview, for detection and management of bladder cancer; Visonac, for acne treatment; Cevira, used in HPV and precancerous lesions of the cervix treatment; and Lumacan, applied in colorectal cancer treatment. Furthermore, It owns a Photocure Technology platform, which develops photodynamic technology for diagnosis and therapy. The firm is a parent of a wholly owned entity, Photocure Inc.
Officers
The intrinsic value of one PHO stock under the Base Case scenario is 69.23 NOK.
Compared to the current market price of 48.7 NOK, Photocure ASA is Undervalued by 30%.